Table 2

Univariable associations between various factors and receiving contraception counselling

ExposuresCategoriesNo contraception counselling (n=103, 22%)
n (%) or mean±SD
Any contraception counselling (n=375, 78%)
n (%) or mean±SD
OR (95% CI)None or one contraception counselling specialty (n=268, 56%)
n (%) or mean±SD
At least 2 contraception counselling specialties (n=210, 44%)
n (%) or mean±SD
OR (95% CI)No rheumatology contraception counselling (n=206, 43%)
n (%) or mean±SD
Rheumatology contraception counselling (n=272, 57%)
n (%) or mean±SD
OR (95% CI)
AgeContinuous years, 10 years older35.7±8.333.0±7.80.64 (0.48 to
0.85)
34.8±8.131.9±7.60.63 (0.50 to 0.79)34.8±7.932.6±7.90.71 (0.56 to
0.90)
RaceAfrican American41 (17)207 (83)1.00 (ref)132 (53)116 (47)1.00 (ref)99 (40)149 (60)1.00 (ref)
Caucasian33 (28)85 (72)0.51 (0.30 to
0.86)
76 (64)42 (36)0.63 (0.40 to 0.99)56 (47)62 (53)0.74 (0.47 to
1.14)
Other/Asian/
AI/NA
21 (24)65 (76)0.61 (0.34 to
1.11)
46 (53)40 (47)0.99 (0.61 to 1.62)39 (45)47 (55)0.80 (0.49 to
1.31)
Immuno- suppressionNo HCQ16 (24)50 (76)1.00 (ref)40 (61)26 (39)1.00 (ref)29 (44)37 (56)1.00 (ref)
HCQ87 (21)325 (79)1.20 (0.65 to
2.20)
228 (55)184 (45)1.24 (0.73 to 2.11)177 (43)235 (57)1.04 (0.62 to
1.76)
No MMF/MPA81 (24)254 (76)1.00 (ref)204 (61)131 (39)1.00 (ref)157 (47)178 (53)1.00 (ref)
MMF/MPA22 (15)121 (85)1.75 (1.04 to
2.95)
64 (45)79 (55)1.92 (1.29 to 2.86)49 (34)94 (66)1.69 (1.13 to
2.54)
No mAb88 (22)316 (78)1.00 (ref)226 (56)178 (44)1.00 (ref)179 (44)225 (56)1.00 (ref)
mAb15 (21)58 (79)1.08 (0.58 to
1.99)
41 (56)32 (44)0.99 (0.60 to 1.64)26 (36)47 (64)1.44 (0.86 to
2.41)
No MTX100 (22)345 (78)1.00 (ref)256 (58)189 (42)1.00 (ref)196 (44)249 (56)1.00 (ref)
MTX3 (9)30 (91)2.90 (0.87 to
9.69)
12 (36)21 (64)2.37 (1.14 to 4.94)10 (30)23 (70)1.81 (0.84 to
3.89)
No CYC100 (21)367 (79)1.00 (ref)262 (56)205 (44)1.00 (ref)202 (43)265 (57)1.00 (ref)
CYC2 (20)8 (80)1.09 (0.23 to
5.21)
5 (50)5 (50)1.28 (0.37 to 4.47)3 (30)7 (70)1.78 (0.45 to
6.96)
No teratogenic76 (26)219 (74)1.00 (ref)187 (63)108 (37)1.00 (ref)144 (49)151 (51)1.00 (ref)
Any teratogenic27 (15)156 (85)2.01 (1.23 to
3.26)
81 (44)102 (56)2.18 (1.50 to 3.17)62 (34)121 (66)1.86 (1.27 to
2.73)
Number of immuno- suppressive medications used08 (35)15 (65)1.00 (ref)18 (78)5 (22)1.00 (ref)14 (61)9 (39)1.00 (ref)
1–394 (21)359 (79)2.04 (0.84 to
4.95)
248 (55)205 (45)2.98 (1.09 to 8.15)190 (42)263 (58)2.15 (0.91 to
5.08)
0–173 (25)216 (75)1.00 (ref)182 (63)107 (37)1.00 (ref)140 (48)149 (52)1.00 (ref)
2–329 (16)158 (84)1.84 (1.14 to
2.97)
84 (45)103 (55)2.09 (1.43 to 3.03)64 (34)123 (66)1.81 (1.23 to
2.64)
  • ORs and 95% CIs are shown in bold when the null effect is excluded at alpha=0.05. OR >1 indicates higher odds of contraception counselling defined; OR <1 indicates lower odds of contraception counselling defined, compared with the reference group.

  • AI/NA, American Indian/Native Alaskan; CYC, cyclophosphamide; HCQ, hydroxychloroquine; mAb, monoclonal antibody (includes rituximab and belimumab); MMF, mycophenolate mofetil; MPA, mycophenolic acid; MTX, methotrexate.